Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe.


Journal

Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213

Informations de publication

Date de publication:
11 10 2020
Historique:
received: 09 06 2020
accepted: 10 07 2020
pubmed: 14 10 2020
medline: 17 8 2021
entrez: 13 10 2020
Statut: epublish

Résumé

Background The aim of this project was to collect real-world evidence and describe treatment patterns for stage III non-small cell lung cancer in Central and Eastern Europe. Based on real-world evidence, an expert opinion was developed, and the unmet needs and quality indicators were identified. Patients and methods A systematic literature search and a multidisciplinary expert panel of 10 physicians from 7 countries used a modified Delphi process to identify quality indicators and unmet needs in patients with stage III non-small cell lung cancer. The profound questionnaire was used to characterize treatment patterns used for stage III non-small cell lung cancer, and a systematic review identified patterns in Central and Eastern Europe. The first questionnaire was completed by a group of medical oncologists, radiation oncologists and pneumologists. The panel of experts attended an in-person meeting to review the results of the questionnaire and to process a second round Delphi. An additional survey was then compiled and completed by the panel. Results A complete consensus was reached by the panel of experts on a set of evidence-based clinical recommendations. The experience-based questionnaire generated a highly variable map of treatment patterns within the region. A list of unmet needs and barriers to quality care were developed with near-unanimous consent of the panel of experts. Conclusions The current landscape of diagnostic and therapeutic approaches in Central and Eastern European countries is highly variable. We identified several significant barriers, mainly related to the availability of diagnostic and imaging methods and low rates of chemoradiotherapy with curative intention as initial treatment for unresectable stage III NSCLC.

Identifiants

pubmed: 33048837
doi: 10.2478/raon-2020-0058
pii: /j/raon.ahead-of-print/raon-2020-0058/raon-2020-0058.xml
pmc: PMC7585343
doi:
pii:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-454

Références

BMC Cancer. 2017 Aug 31;17(1):603
pubmed: 28859609
Oncol Lett. 2017 Nov;14(5):5611-5618
pubmed: 29113190
J Thorac Oncol. 2020 Feb;15(2):288-293
pubmed: 31622733
J Thorac Oncol. 2013 May;8(5):630-6
pubmed: 23584295
Clin Transl Oncol. 2020 May;22(5):759-771
pubmed: 31368078
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Pathol Oncol Res. 2015 Apr;21(2):423-31
pubmed: 25194563
Eur Respir Rev. 2019 Jul 8;28(152):
pubmed: 31285288
Ann Thorac Surg. 2014 Jul;98(1):183-90
pubmed: 24775804
Radiother Oncol. 2011 Feb;98(2):238-43
pubmed: 20951453
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Lung Cancer. 2020 Jan;139:185-194
pubmed: 31812889
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Radiol Oncol. 2018 Feb 21;52(3):281-288
pubmed: 30210037
Clin Lung Cancer. 2015 Mar;16(2):80-5
pubmed: 25450877
Clin Transl Oncol. 2012 Aug;14(8):613-8
pubmed: 22855143
Clin Transl Oncol. 2019 Nov;21(11):1464-1471
pubmed: 30903517
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Clin Transl Oncol. 2011 Jul;13(7):460-71
pubmed: 21775273
Radiol Oncol. 2020 May 28;54(2):209-220
pubmed: 32463394
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1008-14
pubmed: 20656419
J BUON. 2007 Jan-Mar;12(1):33-9
pubmed: 17436399
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316

Auteurs

Milada Zemanova (M)

1st Faculty of Medicine of Charles University, Prague, Czech Republic.

Marko Jakopovic (M)

Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.

Karmen Stanic (K)

Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Małgorzata Łazar-Poniatowska (M)

Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.

Martina Vrankar (M)

Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Petronela Rusu (P)

Institute of Oncology "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania.

Tudor Ciuleanu (T)

Institute of Oncology "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania.

Davorin Radosavljevic (D)

Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.

Krisztina Bogos (K)

National Koranyi Institute of TB and Pulmonology, Budapest, Hungary.

Sergiusz Nawrocki (S)

Department of Oncology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH